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ABSTRACT 
Liver failure is a clinical syndrome of various etiologies, manifesting as jaundice, encephalo-
pathy, coagulopathy and circulatory dysfunction, which result in subsequent multiorgan fail-
ure. Clinically, liver failure is classified into four categories: acute, subacute, acute-on-chronic 
and chronic liver failure. Massive hepatocyte death is considered to be the core event in the 
development of liver failure, which occurs when the extent of hepatocyte death is beyond the 
liver regenerative capacity. Direct damage and immune-mediated liver injury are two major 
factors involved in this process. Increasing evidence has suggested the essential role of im-
mune-mediated liver injury in the pathogenesis of liver failure. Here, we review the evolved 
concepts concerning the mechanisms of immune-mediated liver injury in liver failure from 
human and animal studies. Both innate and adaptive immunity, especially the interaction of 
various immune cells and molecules as well as death receptor signaling system are discussed. 
In addition, we highlight the concept of “immune coagulation”, which has been shown to be 
related to the disease progression and liver injury exacerbation in HBV related acute-on-
chronic liver failure.  
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INTRODUCTION 
Liver failure is a severe inability of the 
liver to perform its normal synthetic and 
metabolic function, as clinically character-
ized by jaundice, ascites, encephalopathy and 
coagulopathy, which may lead to multiple 
organ failures and death. Liver failure can 
develop as acute liver failure (ALF) in the 
absence of any pre-existing liver disease, 
acute-on-chronic liver failure (ACLF) in the 
presence of known or unknown chronic liver 
disease, or chronically as a decompensation 
of pre-existing end-stage liver disease( Sarin 
et al., 2009). 
Liver failure may result from various eti-
ologies, among which drugs and long-term 
alcohol consumption are the respective lead-
ing causes of acute (subacute) and chronic 
liver failure in western countries. Neverthe-
less, hepatitis virus infections, primarily 
hepatitis B, as well as other non-hepatotropic 
viruses are the main causes of liver failure in 
the Asian and developing countries (Nanda 
et al., 1994; Tibbs and Williams, 1995; Wil-
liams, 1996; Tandon et al., 1999; Chu et al., 
1999). 
In the development of liver failure, mas-
sive hepatocellular death is considered to be 
the core event, as accompanied by the in-
flammatory cell infiltration and hepatic is-
chemic injury. Liver failure occurs when the 
rate and extent of hepatocellular death ex-
ceeds the regenerative capacity of the liver. 
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The direct injury and immune mediated liver 
injury both contribute to these pathological 
processes. More and more evidence suggest-
ed that the immune response plays a pivotal 
role in the pathogenesis of liver failure, es-
pecially the activation of immune cells, in-
cluding kuppfer cells, dendritic cells (DCs), 
natural killer (NK) cells, cytotoxic T lym-
phocytes (CTLs), regulatory T (Treg) cells, 
etc., and their production of cytokines. In the 
early phase of virus induced ALF/ACLF, 
kuppfer cells produce quantities of proin-
flammatory cytokines, including tumor ne-
crosis factor-alfa (TNF-, interlukin-1 (IL-
1) and interferon-gama (IFN-which lead 
to hepatocellular injury. Additionally, kup-
pfer cells that express procoagulant fibrino-
gen-like protein (FGL2)/fibroleukin pro-
thrombinase also promote hepatocyte death 
by initiating “immune coagulation”. 
NK/NKT cells are also involved in this 
stage, eliminating the infected hepatocytes 
by either mediating apoptosis through Fas/ 
FasL and natural killer group 2D (NKG2D)/ 
NKG2DL pathway, or secreting IFN- and 
perforin. DCs is responsible for presenting 
the antigens to T helper cells, and the acti-
vated lymphocytes are recruited to liver by 
certain chemokines. In the later period, adap-
tive immune response takes priority. CTLs 
directly kill the infected hepatocytes through 
Fas/FasL or perforin pathway, or clear the 
virus by secreting antiviral agents. Tregs, 
which are characterized by the production of 
IL-10 and TGF-β, tend to inhibit the prolif-
eration and function of effector T cells and 
modulate the immune response (Figure 1). 
However, the mechanisms involved are 
complex and still remain not fully under-
stood. 
 
 
Figure 1: Proposed mechanism of hepatitis virus-induced and immune-mediated liver injury. The sig-
nificant role of the innate and adaptive immune response, including macrophages and CD4–CD8– 
double negative T cells expressing fgl2, natural killer cells and their production of KCTD9, as well as 
the interaction between dendritic cells and T lymphocytes is shown. KCs, Kupffer cells; NK, natural 
killer cells; Treg, Regulatory T Cell; DNT, double negative T cell; DCs, dendritic cells; IFN-, Interferon 
; TGF-β, transforming growth factor-β; MHV-3, Murine Hepatitis Virus Strain 3; shRNA, short hairpin 
RNA; TNF-R, Tumor Necrosis Factor receptor; KCTD9, Potassium Channel Tetramerisation Domain 
Containing 9, cEts2-HNF4, cEts2-Hepatocyte Nuclear Factor 4;TLR 4, Toll Like Receptor 4; MHC, Ma-
jor Histocompatibility Complex. 
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1. INNATE IMMUNITY 
Both innate and adaptive immunity par-
ticipate in the immune-mediated liver injury 
that leads to liver failure. The innate immune 
system is activated prior to the adaptive im-
mune system, and enables the highly special-
ized adaptive immune system to confer long-
term immunological memory. The innate 
immune system acts as the first-line of de-
fense against invading pathogens and other 
potential threats to the host. Exquisite coor-
dination of multiple innate immune cells is 
crucial to efficiently destroy and clear the in-
vading pathogens and other molecular 
threats. Liver is highly enriched in innate 
immune cells, such as kupffer cells, natural 
killer (NK) cells, NKT cells and dendritic 
cells (DC), which result in unique immune 
responses against microbial pathogens 
(Thomson and Knolle, 2010). There is in-
creasing evidence suggesting that liver plays 
a pivotal role in innate immune responses 
and acts more as an immune organ (Crispe, 
2009; Gao et al., 2008; Racanelli and Re-
hermann, 2006). 
 
1.1 Macrophages / immune coagulation 
system 
Macrophages display a remarkable plas-
ticity and can differentiate functionally into 
M1 and M2 subsets (Yang et al., 2012a). Ac-
tivated M1 macrophages are associated with 
type I cytokines (e.g., TNF-, IL-6 and IFN-
) and exhibits the potent pro-inflammatory 
effects, which promote Th1 immune re-
sponse. On the contrary, activated M2 mac-
rophages release several immunoregulatory 
mediators (e.g., IL-4, IL-10 and IL-13) that 
suppress inflammation and promote tissue 
repair. (Laskin, 2009; Benoit et al., 2008; 
Montaner, 1999; Gordon and Martinez, 
2010). Kupffer cells are the liver resident 
macrophages constituting the majority of tis-
sue macrophages of the body. Normally, na-
ïve KCs is likely to differentiate into M2 
phenotype, maintaining immune tolerance in 
the liver. At the early stage of acute liver 
failure, activated KCs display as the classical 
M1 phenotype and promote liver injury. At 
the resolution stage of ALF, KCs exhibit 
more like M2 macrophages, which produce 
anti-inflammatory and regenerative cyto-
kines (Antoniades, 2012). Several studies 
have demonstrated the correlation between 
the functional states of KCs and the extent of 
liver injury. In a mouse model of ALF in-
duced by concanavalin A (con A), the apop-
tosis and dysfunction of KCs were observed 
and accompanied by the increased produc-
tion of macrophage-related inflammatory cy-
tokines. These observations indicated that 
the deactivation and apoptosis of hepatic 
macrophages may be a potential link be-
tween inflammation and immunoparesis in 
ALF (Yang et al., 2013b). It is reported that 
during ALF, the activated KCs resulted in a 
significant increase in sCD163, which highly 
correlated with fatal outcome (Hiraoka et al., 
2005; Møller et al., 2007). Mita et al. (2005) 
examined 24 patients with fulminant hepatic 
failure who underwent liver transplantation 
and discovered that FasL was expressed pre-
dominantly on liver macrophages, which 
contribute to the severe liver injury through 
Fas/FasL pathway.  
Activation of the immune coagulation 
system has been implicated in the pathogen-
esis of fulminant liver failure. Our previous 
studies have shown the importance of acti-
vated macrophages and its expression of fi-
brinogen-like protein-2 (fgl2) either in a mu-
rine hepatitis virus strain 3 (MHV-3) induced 
fulminant hepatitis animal model or in pa-
tients with hepatitis B-related acute-on-
chronic liver failure. Fgl2 is able to directly 
cleave prothrombin into thrombin, resulting 
in intravascular fibrin deposition within the 
liver and culminating in widespread hepato-
cyte necrosis (Levy et al., 2000; Zhu et al., 
2005, 2006). After m-fgl2 antisense admin-
istration, the overall survival rate increased 
from 0 to 33.33 % in mice with MHV-3-
induced fulminant hepatitis. Furthermore, the 
survival rate in mice receiving dual mfgl2 
and mTNFR1 interference was superior to 
that of mice receiving single-target interfer-
ence (Gao et al., 2010). HBV-induced human 
fgl2 (hfgl2) transcription is dependent on c-
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Ets-2 and mitogen-activated protein (MAP) 
kinase signaling. A positive correlation was 
observed between hfgl2 expression and the 
degree of liver injury, as indicated by the bil-
irubin levels. The hfgl2 expression in pe-
ripheral blood mononuclear cells (PBMC) 
may also be used as a biomarker for monitor-
ing the severity of acute-on-chronic hepatitis 
B and hfgl2 could be a potential target for 
therapeutic intervention (Han et al., 2008; 
Wu et al., 2010).  
 
1.2 Natural killer/natural killer T cells 
Natural killer (NK) cells account for a 
large part of the liver lymphocytes and are 
considered as the first-line effector against 
pathogens (Dong et al., 2007, 2004; Zhang et 
al., 2005). NK cells with expression of 
TRAIL showed strong cytotoxicity against 
primary hepatocytes in the liver injury (Ochi 
et al., 2004). The activated NK cells produce 
plenty of IFN-γ, but the liver injury was ab-
solutely independent on IFN-γ. Perforin and 
FasL were also confirmed to be two dispen-
sable effectors in the NK cell-mediated liver 
injury (Dong et al., 2007). A variety of 
groups have reported the critical role of NK 
cells in the pathogenesis of liver injury. Zou 
et al. (2010) in our lab has investigated the 
role of liver NK cells in the development of 
hepatocyte necrosis in both fulminant hepat-
ic failure (FHF) and acute-on-chronic liver 
failure (ACLF) due to viral infection. After 
MHV-3 infection, a large number of NK 
cells were recruited into the liver from pe-
ripheral blood, spleen and bone marrow. 
Meanwhile, the cytotoxic activity of NK 
cells was also significantly enhanced with an 
increasing intracellular IFN-γ and TNF-α 
production. Both Fas/FasL and 
NKG2D/NKG2DL pathways were found to 
contribute to liver NK cell-mediated hepato-
cyte toxicity in the FHF model. In patients 
with acute-on-chronic hepatitis B liver fail-
ure (ACHBLF), the accumulation of liver 
NK cells and increased expression of FasL 
and cytotoxicity receptors (NKp30 and 
NKp46) on peripheral NK cells were corre-
lated with disease progression (Zou et al., 
2010). Our colleagues also observed a newly 
identified potassium channel tetramerisation 
domain containing 9 (KCTD9), which was 
highly expressed in peripheral and hepatic 
NK cells from ACHBLF patients, and its ex-
pression had a positive correlation with the 
severity of liver injury. Inhibition of KCTD9 
by shRNA resulted in reduced cytotoxic 
function. These results suggest the involve-
ment of KCTD9 in NK cell activation. 
Natural killer T cells are a unique subset 
of T cells expressing surface markers of both 
T cells and NK cells. NKT cells are consid-
ered to be an important role in Con A-
induced liver injury by producing IFN- and 
IL-4 as well as Fas-mediated hepatocyte 
apoptosis (Tiegs, 2007). Zhao N et al. (2011) 
demonstrated a novel role of V T cells 
in conducting a protective effect against Con 
A-induced fulminant hepatitis through nega-
tively regulating the function of NKT cells in 
an IL-17A–dependent manner. This finding 
indirectly confirmed the role of NKT cells 
involved in the pathogenesis of liver injury. 
Kakimi et al. (2000) found that activated in-
trahepatic NKT cells participate in the con-
trolling of HBV replication by secreting an-
tiviral cytokines (IFN-γ and IFN-α/β) in 
HBV transgenic mice.  
 
1.3 Dendritic cells  
Dendritic cells (DC) are a kind of specif-
ic antigen-presenting cells (APC) and com-
paratively abundant in the liver. DC consti-
tutes the body’s primary source of type I in-
terferon (IFN), which regulate the local im-
mune responses in liver. Recent studies have 
indicated that the number and function of 
DCs are closely associated with the progno-
sis of HBV-associated ACLF patients with 
different therapies. Zhang et al. (2008a) re-
ported that activated pDCs accumulated in 
large numbers in liver of the ACHBLF pa-
tients, and produced IFN-, which subse-
quently induced IL-12 and IL-10 production 
via toll-like receptor-9 ligation in liver-
infiltrating lymphocytes. Zhao et al. (2012) 
indicated that higher mDC numbers at base-
line and the recovery of mDC number at the 
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end of treatment may represent a prognostic 
marker for favorable response to corticoster-
oid treatment in ACHBLF patients. Khanam 
et al. (2014) have found that the frequencies 
of circulating and intrahepatic myeloid 
(mDCs) and plasmacytoid (pDCs) dendritic 
cells (DCs) increased significantly post-G-
CSF treatment in ACLF patients along with 
improved clinical parameters serum bilirubin 
and international normalized ratio (INR). 
 
1.4 Toll-like receptors (TLRs) 
Toll-like receptors (TLRs) play a key 
role in the innate immune response to invad-
ing pathogens. The Toll-like receptor 4 
(TLR4) expresses mainly on macrophages 
and plays an important role in mediating 
macrophage activation and subsequent pro-
duction of pro-inflammatory cytokine, which 
leads to the progression of severe liver inju-
ry. Increasing studies have focused on the 
potential mechanisms of TLR4 in the devel-
opment of liver failure as well as the effect 
of its antagonists for treatment. In a recent 
study, a TLR4 antagonist (E5564) was used 
to treat the rats with d-galactosamine (d-
galactosamine) and lipopolysaccharide 
(LPS)-induced acute liver failure, and re-
markably reduced the liver injury and im-
proved the overall survival rate of these rats. 
The TLR4 antagonist may work through 
blocking endotoxin-induced TNF- over-
production of macrophages (Kitazawa et al., 
2010). Another study also suggested that 
TLR4 in the liver and extrahepatic organs 
were activated in acetaminophen (APAP)-
induced acute liver failure and lead to the 
progression of ALF and multiorgan dysfunc-
tion (MOD). And the administration of the 
TLR4 antagonist STM28 prevented liver in-
jury and associated MOD (Shah et al., 2013). 
Fisher et al. (2013) compared wild-type mice 
with TLR4-mutant, E5564 (a TLR4 antago-
nist) -treated, and KC-depleted mice in liver 
pathology and survival rate after APAP ad-
ministration. All groups had significant liver 
injury but only wild-type mice had markedly 
worse survival. These results also pointed to 
a link between TLR4 and KCs in the APAP 
induced ALF and confirmed the efficiency of 
TLR4 antagonism in treating ALF. Except 
TLR 4，TLR3 is also found to be important 
in innate immunity and is responsible for 
recognizing viral pathogens. Rong  et al. 
(2013) revealed that the prevalence of TLR3 
1234CT genotype and T allele was signifi-
cantly increased in CHB patients with ACLF 
than those without ACLF. TLR3 C1234T 
polymorphism could be a risk factor for the 
development of chronic HBV infection, es-
pecially the CHB-related ACLF.  
 
2. ADAPTIVE IMMUNITY 
2.1 Cellular immunity 
It is commonly accepted that the adaptive 
immunity plays an essential role in the path-
ogenesis of HBV related ACLF. The clear-
ance of virus depends primarily on two 
ways: the direct killing of infected hepato-
cytes by cytotoxic T lymphocytes (CTLs) 
through Fas/FasL or perforin pathway, or by 
the release of IFN-(Guidotti et al., 1999; 
Thimme et al., 2003; Bertoletti et al., 2003; 
Kondo et al., 2004). 
2.1.1 T cells  
T cell responses, especially T helper cell 
and CTL responses are of considerable im-
portance in viral control and immune-
mediated liver damage. The reduction of 
CD4+T lymphocytes, predominantly con-
ventional CD4+T cells, was observed in 
ACHBLF patients. And the development of 
suppressive CD4+ Tregs greatly prevails 
over conventional CD4+T cells, constituting 
important characteristics of adaptive 
immune dysfunction of HBV related 
ACLF (Dong et al., 2013). CD8+ CTLs are 
the predominant effector T lymphocytes that 
contribute to the extensive hepacellular death 
in virus induced liver failure. The elevated 
PD-1 expression could promote CD8+ T 
cells apoptosis and pathogenic CD8+ T-cell 
responses and liver damage. It is found that 
in ACHBLF patients, the expression of PD-1 
and PD-L1 was positively correlated with 
disease progression, and the PD-1 expression 
on effector CD8+ T cells was lower than 
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those on other CD8+ T cells, which maybe 
accounted for the liver failure (Zhang et al., 
2008b; Liu et al., 2010a, b).  
2.1.2 Regulatory T cells (Tregs)  
CD4+CD25+ regulatory T cells (Tregs) 
are able to suppress the proliferation and 
function of effector T cells and maintain 
immunological tolerance to self and foreign 
antigens (Stoop et al., 2005; Franzese et al., 
2005). However, the relationship between 
the frequency and function of CD4+CD25+ 
Tregs and the severity of ACLF has not 
reached broad consensus. Yang et al. 
(2012b) showed that the CD4(+)CD25(high) 
Tregs prevalence in peripheral blood is high-
ly increased and positively correlated with 
HBV DNA load, suggesting its indicative of 
disease severity in ACLF or CHB patients. A 
study showed activated T cells and chemo-
kine receptors could induce Tregs and recruit 
other inflammatory cells in liver, but the in-
creased expression of regulatory T cells in 
liver could not effectively downregulate the 
activation of inflammatory cells in ACLF 
(Khanam et al., 2010). High mobility group 
box-1 (HMGB1) protein, which is involved 
in the process of endotoxemia, can weaken 
the immune activity of Treg cells and favors 
liver failure in patients with chronic HBV in-
fection (Wang et al., 2010). Fibrinogen-like 
protein 2 (Fgl2) was also an important effec-
tor molecular for Tregs that contributed to 
the susceptibility to MHV-3-induced fulmi-
nant hepatitis (Shalev et al., 2009). CD3+ 
CD4-CD8-double negative T cells (DNT) 
are a novel subset of regulatory T cells, 
which exacerbate the disease progression in 
MHV-3-induced fulminant hepatitis by ex-
pressing Fgl2 (Wu et al., 2012). The number 
of newly identified CD39+FoxP3+CD4+ 
Treg cells weas detected significantly less in 
chronic active hepatitis B and ACLF patients 
than those in asymptomatic HBV carriers. 
The increased proportions of circulating 
CD39+ Tregs were positively correlated with 
serum viral load, but inversely correlated 
with serum ALT level, indicating that these 
CD39+ Tregs may be associated with the 
HBV disease progression (Tang et al., 2012). 
Recently, Zhang et al. (2012) has identified 
the heterogeneity of human CD4(+)Foxp3(+) 
T cells. The circulating and intrahepatic 
CD4(+)CD45RA(-)Foxp3(hi)-activated Tregs 
(aTregs) were selectively increased in pa-
tients with active CHB and ACLF. In both 
peripheral blood mononuclear cells 
(PBMCs) and livers, ACLF patients showed 
a dramatic elevation of interleukin 17A-
secreting CD45RA(-)Foxp3(lo) non-suppres-
sive T cells (non-Tregs), which were shown 
to be associated with severe liver damage. 
2.1.3 Th17 cells 
Th17 cells, which are characterized by 
the production of IL-17 and IL-21, have re-
cently been identified as the third distinct 
subset of effector T cells. IL-21 could pro-
mote Th17 differentiation in a STAT3-
dependent manner, and induce the release of 
cytokines such as IL-17 and IFN-which 
may involved in the pathogenesis of ACLF 
(Wei et al., 2007; Hu et al., 2011). Th17 cells 
and Treg cells are with reciprocally regulated 
differentiation and function. TGF- can in-
duce Treg-specific transcription factor 
Foxp3, while the addition of IL-6 to TGF-  
can inhibit the generation of Treg cells and 
induce Th17 cells. Frequency and function 
of these two cell subsets vary in patients with 
chronic hepatitis B. The fine balance be-
tween Th17 and Treg cells is crucial for 
maintenance of immune homeostasis (Zhao 
et al., 2010; Ye et al., 2010). In recent years, 
the points on the ratio of Th-17/Treg cells in 
ACLF patients and its relationship with the 
disease prognosis remain controversial. Zhai 
et al. (2011) demonstrated both Th17 and 
FoxP3(+) Treg cells in the peripheral blood 
were increased in ACLF patients and the ra-
tio of Th-17 to Treg cells was associated in-
versely with the survival of ACLF patients. 
Niu Y  et al. found that liver IL-17(+) T cells 
increased markedly in the ACLF patients, 
while the Foxp3+ T cells did not show a sig-
nificant difference between ACLF and CLF 
patients. In addition, the ACLF group 
showed a dramatically higher IL-17(+)/ 
Foxp3(+) ratio than the CLF group, and the 
imbalance between IL-17(+) and Foxp3(+) T 
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cells in the liver may lead to progression of 
the disease(Niu et al., 2011). Restoring the 
Treg cell/Th17 cell ratio during the follow-
up phase of ACLF could maintain the im-
mune system at a steady state, which favours 
good prognosis (Niu et al., 2013). Neverthe-
less, Zhang et al. (2013) made a different 
conclusion that Th17 cells increased while 
Treg cells decreased in the recovery phase of 
ACLF, and a high ratio of Th-17 to Treg 
cells leads to a better prognosis. Thus, more 
investigations are needed to carry out on this 
issue. 
 
2.2 Humoral immunity 
HBV-associated acute liver injury is be-
lieved to be prominently mediated by the 
cellular immune response (Thimme et al., 
2003) and the role of humoral immune re-
sponse in this process is poorly understood. 
The viral clearance and antibody response 
are more rapid and active in fulminant hepa-
titis B than in traditional cases of acute hepa-
titis B (Trepo et al., 1976; Tabor et al., 1976; 
Gimson et al., 1983). A recent study analyz-
ing liver tissues from two patients show that 
HBV-associated ALF is characterized by an 
overwhelming B cell response centered in 
the liver with massive intrahepatic produc-
tion of IgG and IgM by infiltrating plasma 
cells against the hepatitis B core antigen 
(HBcAg) of HBV, implicating a major role 
of B cell immunity in the pathogenesis of 
HBV-associated ALF (Farci et al., 2010). 
Thus, the dynamic changes of humoral im-
munity in the development of HBV-
associated ALF and underlying mechanisms 
need further investigation. 
 
3. CYTOKINES  
In the development of liver failure, a 
prominent phenomenon of host immune re-
sponse is the cascade activation of proin-
flammatory cytokines, displaying as“sepsis-
like”immune paralysis (Wasmuth et al., 
2005). Proinflammatory and anti-inflamma-
tory cytokines in the pathogenesis of liver in-
jury were extensively investigated, and cyto-
kines including TNF-, IFN- and IL-6 etc 
were identified to be of considerable im-
portance(Galun et al., 2002; Yin et al., 2003; 
Odeh et al., 2004; Rutherford et al., 2007; 
Nagaki et al., 2008). 
TNF-is considered exhibiting different 
effects in different phases. In the early phase 
of liver injury, high level of TNF-protects 
hepatocytes from apoptosis, favors their re-
pairing and regeneration. Whereas continu-
ous increase of TNF-induces the apoptosis 
and necrosis of hepatocytes. The increase of 
blood TNF-as well as overexpression of 
TNF-receptor 1 is directly correlated to the 
mortality of patients with liver failure (To-
kushige et al., 2000; Nagaki et al., 2000). In 
D-GalN/LPS-induced murine fulminant he-
patic failure, TNF-expression was also en-
hanced remarkably (Lian et al., 2010). 
IFN-γis primarily produced by NK cells 
and activated T cells, and induces macro-
phage activation and a delayed-type hyper-
sensitivity response that damages the liv-
erAndo et al., 1993The vital role of IFN-
γin the pathogenesis of HBV or ConA/LPS 
induced ALF were proved by several stud-
ies(Nicoletti et al., 2000; Shimizu et al., 
2002). TNF- and IFN-were both highly 
expressed in the liver of ACLF patients 
compared with those in CHB patients. The 
increase of IFN-was due to the recruitment 
of CD4+ and CD8+ T lymphocytes while the 
upregulation of TNF-is associated with the 
enhancement of Kupffer cells Zou et al., 
2009
IL-6 is also produced mainly by macro-
phages and T cells, possessing pleiotropic 
characteristics of both anti-inflammatory and 
pro-inflammatory cytokine. A number of 
studies have suggested the relationship be-
tween increased hepatic and circulating IL-6 
expression and the severity of liver injury in 
acute/subacute liver failure in human (Jin et 
al., 2006). Another animal study also sug-
gested the Con A-induced liver injury is me-
diated by CD4+ T cells acting within the liv-
er, and at least in part through the secretion 
of IL-6(Cao et al., 1998). In ACHBLF pa-
tients receiving glucocorticoid treatment, IL-
6 and TNF-α levels were statistically lower, 
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while the SOCS1 transcription level was 
higher with better prognosis (Zhang et al., 
2014). Nonetheless, some investigators dis-
covered IL-6 was protective for liver damage 
induced by ConA, acetaminophen, carbon 
tetrachloride (CCL4) or other stimulus. This 
effect is probably mediated by the induction 
of anti-apoptotic proteins including Bcl-xL, 
Bcl-2 and FLIP, which activate the signal 
transducer and activator of transcription 3 
(STAT3) pathway and inhibit IFN-
secretion (Mizuhara et al., 1994, 1996; Ko-
valovich et al., 2001, 2000; Hong et al., 
2002; Masubuchi et al., 2003; Taub, 2003; 
Klein et al., 2005). In an anti-CD137 mAb-
induced liver injury mice model, ectopic IL-
6 expression prevented CD8+ T cell-
mediated liver damage by increasing accu-
mulation of Gr-1+CD11b+ myeloid derived 
suppressor cells (MDSCs) in the liver 
(Cheng et al., 2011). 
IL-17, the characteristic cytokine pro-
duced by Th 17 cells，is involved in the 
mobilization, recruitment and activation of 
immune cells. IL-17 induces IL-8 mediated 
neurophils recruitment in liver, resulting in 
the liver injury due to HBV infection (Ye et 
al., 2010). In ACHBLF patients, the in-
creased serum IL-17 level contributes to the 
immune activation and disease aggravation 
(Yang et al., 2013a). 
The anti-inflammatory cytokine IL-10 
can inhibit the activation of monocytes by 
downregulating NF-kB, and reduce the pro-
duction of pro-inflammatory cytokines. 
However, the overexpression of IL-10 medi-
ates the immunoparesis contributing to prog-
nosis in ALF. Berry PA  et al. showed that 
admission levels and early changes in serum 
IL-10 are predictive of poor outcome as well 
as the pro-inflammatory cytokine (TNF-
and IL-6) in acute liver failure(Berry et al., 
2010; Antoniades et al., 2008). 
 
4. DEATH RECEPTOR SIGNALING 
Death receptor-induced hepatocyte apop-
tosis plays a large part in the development of 
acute liver failure. Death receptors that are 
expressed on hepatocytes include Fas 
(CD95), tumour necrosis factor receptor 1 
(TNF-R1), tumor necrosis factor-related 
apoptosis inducing ligand receptors 1 and 2 
(TRAIL-R1/TRAIL-R2), death receptor 3 
and 6. These death receptors can trigger in-
tracellular signalling pathways when bound 
to their respective ligands (Yin and Ding, 
2010; Malhi et al., 2006).  
Fas can be expressed on a variety of cells 
in liver, including hepatocytes, stellate cells, 
kupffer cells, endothelial cells and cholangi-
ocytes(Ni et al., 1994; Saile et al., 1997; 
Muschen et al., 1998; Cardier et al., 1999; 
Ueno et al., 2000). The liver is very sensitive 
to Fas-induced apoptosis. Experimental stud-
ies have suggested that apoptosis via the 
Fas/FasL signaling pathway may play an im-
portant role in the development of acute liver 
failure. In mice, administration anti-Fas ago-
nistic antibody causes rapid death due to 
fulminant hepatitis (Ogasawara et al., 1993). 
In human fulminant hepatic failure, Fas was 
found to be highly expressed on a large 
number of hepatocytes, while FasL was de-
tected expressing on both liver and peripher-
al lymphocytes, and the soluble FasL in se-
rum significantly increased as well(Ryo et 
al., 2000; Tagami et al., 2003). As previously 
mentioned, Fas/FasL pathway also contrib-
utes to the liver NK cell-mediated hepatocyte 
injury in both mouse FHF and human HBV-
ACLF (Zou et al., 2010). 
TNF-R1 is highly expressed on hepato-
cytes. Activation of TNF-R1 can mediate 
NF-κB activation, apoptosis or necroptosis, 
and leads to different outcomes, which are 
determined by distinct TNF receptor-
associated signaling complexes (Bantel and 
Schulze-Osthoff, 2012). TNF- has been 
shown to be an important mediator of ALF 
due to CCL4 or hepatic ischemia–reper-
fusion injury, but not acetaminophen induced 
injury. Accumulating evidence suggests that 
oxidative stress may sensitize the ischemic 
liver to TNF-, leading to potentially mas-
sive apoptosis (Riordan and Williams, 2003). 
TNF receptor gene deletion could delay dis-
ease progression and attenuate disease sever-
ity in experimental acute liver failure (Bé-
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meur et al., 2010). Anti-TNF-α polyclonal 
antibody was beneficial to protect the rats in 
human serum albumin (HSA) and D-
Gal/LPS induced ACLF (Yang et al., 2014). 
It has been shown in vitro that TNF  can 
enhance hepatocyte FasL-mediated cytotoxi-
city, and in turn, TNF -induced apoptosis 
was associated with Fas and FasL upregula-
tion (Kuhla et al., 2008). The serum TNF- 
and soluble FasL can be used as biomarkers 
in non-acetaminophen-induced acute liver 
failure (Singhal et al., 2009).  
TRAIL has several receptors, among 
which TRAIL-R1 and TRAIL-R2 are so-
called full functional receptors. When en-
gaged, they initiate a similar cascade as Fas 
does, recruiting FADD and initiator caspase-
8 or caspase-10 to the receptor complex, and 
induce hepatocyte apoptosis (Yin and Ding, 
2003). Data are conflicting about the hepato-
toxicity of TRAIL. Hepatocytes are sensitive 
for TRAIL-mediated apoptosis in vitro, but 
TRAIL induces no apoptosis in healthy liv-
ers in vivo. It has been shown that TRAIL 
enables the organisms to specifically kill vi-
rus-infected hepatocytes (Mundt, et al., 
2003). However, little data suggests a direct 
correlation between TRAIL and liver failure. 
 
SUMMARY 
The pivotal role of immune mediated liv-
er injury in the pathogenesis of liver failure 
has been commonly accepted. The activation 
of various immune cells and secretion of cy-
tokines initiate immune response in the early 
phase and cause massive hepatocyte death. A 
number of immune cells and molecules 
modulate the balance of pro- and anti-
inflammatory factors through different path-
ways. Once the balance is broken, the host 
immune disorder leads to uncontrolled im-
mune responses and subsequent severe liver 
damage that beyond liver regeneration. The 
mechanisms involved in the immune mediat-
ed liver injury, especially the interaction 
among different immune cells are complex 
and need further investigation. These novel 
theories would provide new strategies to 
control the unbalanced immune response and 
thus beneficial for managing patients with 
liver failure. 
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